GXYLT2 Activators
GXYLT2, also known as Glucoside Xylosyltransferase 2, is an enzyme encoded by the GXYLT2 gene in humans. GXYLT2 is involved in the post-translational modification of certain proteins through the addition of xylose-glucose disaccharides to specific serine residues in the consensus sequence of epidermal growth factor-like (EGF-like) repeats, a type of protein domain found in a variety of cell surface and secreted proteins, including Notch receptors.
The activity of GXYLT2 is crucial for the regulation of Notch signaling, a highly conserved cellular communication pathway that influences cell fate determination, differentiation, proliferation, and apoptosis. The addition of sugars to EGF-like repeats by GXYLT2 is part of the glycosylation process, which can affect the folding, stability, and interaction of proteins with other molecules, ultimately modulating the Notch signaling pathway.Notch signaling is implicated in a variety of developmental processes and has been shown to play roles in the pathology of several diseases, including cancers and disorders of the cardiovascular system. Proper glycosylation by enzymes like GXYLT2 is essential for the correct function of the Notch pathway, as alterations in this process can lead to aberrant signaling and disease.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Uridine 5′-diphosphoglucose disodium salt from Saccharomyces cerevisiae | 28053-08-9 | sc-222402 sc-222402A | 10 mg 25 mg | $27.00 $34.00 | ||
As a substrate for glycosyltransferases, UDP-Glucose availability could indirectly influence GXYLT2 activity by providing necessary substrates. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A disrupts Golgi structure and function, potentially impacting glycosylation processes and indirectly GXYLT2 activity. | ||||||
Swainsonine | 72741-87-8 | sc-201362 sc-201362C sc-201362A sc-201362D sc-201362B | 1 mg 2 mg 5 mg 10 mg 25 mg | $138.00 $251.00 $631.00 $815.00 $1832.00 | 6 | |
An inhibitor of Golgi alpha-mannosidase II, Swainsonine can alter glycosylation patterns, potentially affecting GXYLT2. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Tunicamycin inhibits N-linked glycosylation, which might indirectly influence O-glycosylation and GXYLT2 activity. | ||||||
Castanospermine | 79831-76-8 | sc-201358 sc-201358A | 100 mg 500 mg | $184.00 $632.00 | 10 | |
An inhibitor of glucosidases, Castanospermine might affect glycosylation processes, potentially influencing GXYLT2. | ||||||
Deoxynojirimycin | 19130-96-2 | sc-201369 sc-201369A | 1 mg 5 mg | $73.00 $145.00 | ||
This α-glucosidase inhibitor can impact glycosylation, potentially altering GXYLT2 activity. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin elevates cAMP levels, which can modulate various cellular processes, potentially impacting glycosylation and GXYLT2. | ||||||
Kifunensine | 109944-15-2 | sc-201364 sc-201364A sc-201364B sc-201364C | 1 mg 5 mg 10 mg 100 mg | $135.00 $540.00 $1025.00 $6248.00 | 25 | |
An inhibitor of mannosidase I, Kifunensine can affect glycosylation pathways, potentially impacting GXYLT2. | ||||||
D-Glucosamine | 3416-24-8 | sc-278917A sc-278917 | 1 g 10 g | $201.00 $779.00 | ||
Glucosamine is involved in glycosylation processes and could indirectly influence GXYLT2 activity. | ||||||